The estimated Net Worth of Oliver Schacht is at least $606 Thousand dollars as of 31 March 2023. Dr Schacht owns over 12,469 units of Opgen Inc stock worth over $39,832 and over the last 4 years he sold OPGN stock worth over $0. In addition, he makes $565,869 as CEO and Pres & Director at Opgen Inc.
Dr has made over 6 trades of the Opgen Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 12,469 units of OPGN stock worth $25,187 on 31 March 2023.
The largest trade he's ever made was exercising 38,750 units of Opgen Inc stock on 2 March 2022 worth over $78,275. On average, Dr trades about 10,004 units every 73 days since 2020. As of 31 March 2023 he still owns at least 19,719 units of Opgen Inc stock.
You can see the complete history of Dr Schacht stock trades at the bottom of the page.
Dr. Oliver Schacht is the CEO, Pres & Director at Opgen Inc.
As the CEO and Pres & Director of Opgen Inc, the total compensation of Dr Schacht at Opgen Inc is $565,869. There are no executives at Opgen Inc getting paid more.
Dr Schacht is 49, he's been the CEO and Pres & Director of Opgen Inc since . There are 7 older and no younger executives at Opgen Inc. The oldest executive at Opgen Inc is Dr. G. Terrance Walker Ph.D., 62, who is the Sr. VP of R&D.
Oliver's mailing address filed with the SEC is C/O OPGEN, INC. 9717 KEY WEST AVE., SUITE 100, ROCKVILLE, MD, 20850.
Over the last 9 years, insiders at Opgen Inc have traded over $12,018 worth of Opgen Inc stock and bought 4,331,782 units worth $1,198,700 . The most active insiders traders include Evan/ Fa Jones, Capital, Llcjones Evan/ Fa ..., and Capital, Llc J Ven. On average, Opgen Inc executives and independent directors trade stock every 78 days with the average trade being worth of $280,277. The most recent stock trade was executed by Johannes Bacher on 31 March 2023, trading 6,434 units of OPGN stock currently worth $12,997.
opgen, inc. (nasdaq: opgn) is harnessing the power of informatics and genomic analysis to provide complete solutions for infection prevention and treatment. using our large and ever-growing acuitas lighthouse® knowledgebase of pathogens from around the world, we are developing disruptive technologies aimed to shift the paradigm for managing infectious diseases. today, through our clia-certified clinical laboratory services, we provide rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. our fda-cleared, ivd products rapidly identify pathogens in positive blood cultures.
Opgen Inc executives and other stock owners filed with the SEC include: